InsidersTradesSigma
Follow the DarioHealth Corp. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, DarioHealth Corp. has logged 61 public disclosures. Market capitalisation: €72.2m. The latest transaction was filed on 28 July 2026 (C). Among the most active insiders: Raphael Erez. Every trade is accessible without an account.
61
Insider Decl.
n/a
Thresholds
€135,609
10 ops.
Buy Volume
€2m
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate DarioHealth Corp. Strong Buy (bullish), based on 5 analysts. Average price target: US$14.00.
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,078 of 29,064 companies
22.2
score / 100
Value4
Quality40
FCF yld-36%
Earn yld-85%
EV/EBITDA·
ROE-60%
Gross mgn57%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 July 2026
Declarations61 total
965 shares@ US$19.1016.1% of flowCommon StockSEC:0001104659-26-087626:0
14,430 shares@ US$6.930.14% mcap83.9% of flowCommon StockSEC:0001104659-26-087626:1
Canonical exit: 21 Oct 2026 (T+90)
30,000 shares0Common StockSEC:0001104659-25-090098:0
20,000 shares0Common StockSEC:0001104659-25-090097:0
20,000 shares0Common StockSEC:0001104659-25-090019:0
20,000 shares0Common StockSEC:0001104659-25-090007:0
60,000 shares0Common StockSEC:0001104659-25-090006:0
5,000 shares0Common StockSEC:0001104659-25-090004:0
20,000 shares0Common StockSEC:0001104659-25-090002:0
20,000 shares0Common StockSEC:0001104659-25-089997:0
20,000 shares0Common StockSEC:0001104659-25-089996:0
40,000 shares@ US$0.5347.5% of flowCommon StockSEC:0001104659-25-084035:0
Canonical exit: 25 Nov 2025 (T+90)
500,000 shares0Common StockSEC:0001104659-25-049388:0
30,000 shares0Common StockSEC:0001104659-25-016923:0
5,000 shares@ US$0.909221.2% of flowCommon StockSEC:0001104659-24-118926:0
Canonical exit: 10 Feb 2025 (T+90)
5,000 shares@ US$0.844219.0% of flowCommon StockSEC:0001104659-24-099353:0
Canonical exit: 9 Dec 2024 (T+90)
5,000 shares@ US$0.818218.3% of flowCommon StockSEC:0001104659-24-098312:0
Canonical exit: 4 Dec 2024 (T+90)
5,000 shares@ US$0.880.2% of flowCommon StockSEC:0001104659-24-094109:0
Canonical exit: 25 Nov 2024 (T+90)
5,000 shares@ US$0.934520.8% of flowCommon StockSEC:0001104659-24-092420:0
Canonical exit: 19 Nov 2024 (T+90)
5,000 shares@ US$0.930.2% of flowCommon StockSEC:0001104659-24-092417:0
Canonical exit: 18 Nov 2024 (T+90)
2,000 shares@ US$0.890.1% of flowCommon StockSEC:0001104659-24-091264:0
Canonical exit: 14 Nov 2024 (T+90)
5,000 shares@ US$0.919720.6% of flowCommon StockSEC:0001104659-24-091267:0
Canonical exit: 17 Nov 2024 (T+90)
70,000 shares0Common StockSEC:0001104659-24-032412:0
400,000 shares0Common StockSEC:0001104659-24-032416:0
80,000 shares0Common StockSEC:0001104659-24-032408:0
25 of 61 declarations
关于 DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) 是一家在美国纳斯达克市场上市的美国数字健康公司。该公司成立于2011年，最初以直接面向消费者的模式发展，此后演变为更广泛的B2B2C战略，服务于雇主、健康计划、制药合作伙伴、提供商和消费者。其运营总部位于纽约，部分技术和公司历史通过子公司运营与以色列相关联。([dariohealth.com](https://www.dariohealth.com/articles/a-different-approach-to-health-care/?utm_source=openai)) DarioHealth的核心主张是一个用于慢性病管理和全人护理的集成数字平台。该公司将自己定位为以消费者为主导、临床驱动，结合了移动工具、互联设备、指导、行为支持和数据驱动的参与。其主要解决方案领域现在涵盖心血管代谢护理，包括糖尿病、高血压、肥胖症和GLP-1支持，以及肌肉骨骼护理和行为健康。该平台旨在提高依从性、加深会员参与度，并为商业合作伙伴提供可衡量的临床和经济成果。([dariohealth.com](https://www.dariohealth.com/?utm_source=openai)) 从竞争角度来看，DarioHealth在一个竞争激烈的数字健康市场中运营，差异化取决于用户留存、临床证据、多病种广度以及向雇主和支付方渠道销售的能力。收购Twill通过增加行为健康和导航功能，实质性地扩展了产品集，管理层强调在2024年全面整合这些功能，作为迈向更全面的端到端平台的一步。该公司的竞争信息越来越集中于成为一个多病种平台，而不是一个单一病种的点解决方案。([dariohealth.com](https://www.dariohealth.com/pressreleases/dario-announces-integration-twill-capabilities-across-full-platform/?lang=es&utm_source=openai)) 最近的里程碑表明了商业加速战略。2025年1月，DarioHealth宣布与MediOrbis合作，为其GLP-1行为改变解决方案增加处方功能，扩大其医疗减重产品，并支持雇主和直接面向消费者的用例。在2024年期间，该公司还宣布了一项商业重组，旨在精简领导层并加速收入增长，同时报告其核心B2B2C渠道的强劲势头。对于投资者而言，DarioHealth仍然是医疗保健技术领域的小盘成长股：机会在于平台扩展和商业执行，而风险状况仍然反映出激烈的竞争和持续的资金需求。([dariohealth.com](https://www.dariohealth.com/pressreleases/dariohealth-expands-glp-1-solution-prescribing-capabilities-partnership-mediorbis-targeting-employers-d2c-markets/?utm_source=openai))
